The 12th International AIDS Society Conference on HIV Science (IAS 2023)

Another HIV patient may be on the way to a cure following stem cell therapy using wild-type (WT) CCR5 donor cells for a rare and aggressive blood cancer.

Treatment with pitavastatin is associated with a significantly lower risk of cardiovascular (CV) events in people living with human immunodeficiency virus (HIV) as shown in the final analysis of the double-blind, placebo-controlled REPRIEVE trial presented at IAS 2023.

Switching from an integrase inhibitor (INI)-based antiretroviral treatment (ART) regimen to a protease inhibitor (PI)-based regimen falls short of reversing weight gain while on the INI-based regimen, according to the results of the open-label phase IV DEFINE trial.

Voluntary medical male circumcision (VMMC) appears to cut the risk of contracting HIV infection among men who have sex with men (MSM), particularly those who mainly practice insertive anal sex, as shown in a study from China presented at IAS 2023.

Treatment with either bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG + F/TDF) resulted in similarly high and sustained rates of viral suppression in adults with HIV-1* and HBV** coinfection, according to a prespecified secondary analysis of the ALLIANCE trial presented at IAS 2023.

Among treatment-naïve patients with HIV-1* infection, initial treatment combination with doravirine and islatravir (DOR/ISL) was noninferior in achieving virologic suppression (HIV-1 RNA <50 copies/mL) at week 48 compared with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), according to a trial presented at IAS 2023.